Global Partners LP
GLPNASDAQTrading Snapshot
- Day Range
- $45.92 – $46.55
- 52-Week Range
- $835.65 – $1,489.94
- Volume
- $4.04B
- Avg Volume
- $3.76B
- Shares Outstanding
- 7.29B
- Next Earnings
- Dec 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $18.56B
- Last Q Revenue
- $6.79B
- P/E Ratio
- 39.6
- P/S Ratio
- 14.4x
- EPS (TTM)
- $23.60
- Dividend Yield
- 0.02%
- Dilution (1yr)
- −0.6%
Why Investors Own GLP
- ✓High-growth profile — revenue up -8.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 40% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Global Partners LP
GLP
StockOtter · stockotter.spaceAbout Global Partners LP
A company profile for Global Partners LP isn’t available yet — check back soon.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Solvonis says alcohol treatment outpaces GLP-1 drugs in cross-trial comparison
Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) says new analysis of its ketamine-based alcohol treatment shows patients cut heavy drinking days by 67% compared with placebo, more than four months after their last dose.
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?
Eli Lilly's high valuation could limit the stock's future returns. Viking Therapeutics is a much smaller company, and it has a promising GLP-1 asset in VK2735.
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share. Meanwhile, Lilly continues
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking is testing weight loss drug candidates in late-stage trials. The company recently showed that weight loss lasts after taking its drug candidate.
Global Partners (NYSE:GLP) vs. OMV (OTCMKTS:OMVKY) Head to Head Contrast
OMV (OTCMKTS:OMVKY - Get Free Report) and Global Partners (NYSE: GLP - Get Free Report) are both energy companies, but which is the superior business? We will compare the two businesses based on the strength of their ins
NTHM ETF Rotates Into Midstream Energy & GLP-1 Healthcare
The NBI Thematic Rotation ETF (NTHM:TSX) has completed its latest portfolio rebalance, pivoting away from broad tech and industrial momentum to channel capital into midstream energy infrastructure and GLP-1 weight-loss d